Natera is a rapidly-growing diagnostics company with proprietary bioinformatics and molecular technology for analyzing DNA. Nateraâs complex technology has been proven clinically and commercially in the prenatal testing space and the Company is actively researching its applications in the liquid biopsy space for developing products with oncology applications. Since 2009, Natera has launched seven molecular diagnostic tests, many of which are available through major health plans accounting for more than 140 million covered lives in the United States. The Companyâs own robust laboratory processes thousands of genetic tests per month. Nateraâs goal is to transform the way people â both providers and patients â respond to and manage genetic diseases. Source
No articles found.
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading glo...
WuXi Biologics (stock code: 2269.HK), a Hong Ko...
We are a biopharmaceutical company focused on developing our pipeline featuring sp...
We are a biopharmaceutical company focused on d...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
Founded in 1987, Merit Medical set out to build the worldâs most customer-focuse...
Founded in 1987, Merit Medical set out to build...
Medigus is a medical device company specializing in developing minimally invasive ...
Medigus is a medical device company specializin...
We are a global, high-growth diagnostics company committed to improving patient ca...
We are a global, high-growth diagnostics compan...
Guardion Health Sciences is at the forefront of early detection, intervention and ...
Guardion Health Sciences is at the forefront of...
Join the National Investor Network and get the latest information with your interests in mind.